PCSK9 inhibitors in cardiovascular disease: A meta-analysis
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are generally safe and well tolerated in patients with cardiovascular disease (CVD), with mild and acceptable adverse events.
Key Takeaway
In patients with atherosclerotic cardiovascular disease (ASCVD):
PCSK9 inhibitors could ameliorate the lipid profile
They could reduce low-density lipoprotein cholesterol (LDL-C) by >50% and increase high-density lipoprotein cholesterol (HDL-C) by >5% as well as markedly reduce total cholesterol (TC) and triglyceride (TG) levels.
Adverse events of PCSK9 inhibitors were mild and acceptable in patients with CVD. However, attention should be paid to injection-site reactions
PCSK9 inhibitors were generally safe and well tolerated
Why This Matters
PCSK9 inhibitors are an effective strategy to reduce LDL-C and other lipid parameters, particularly in patients not achieving optimal LDL-C levels or probably having high residual CVD risk despite high-intensity statin therapy.
However, physicians are still concerned regarding the efficacy and safety of PCSK9 inhibitors; this knowledge gap has been assessed in this study.
Study Design
This meta-analysis included randomized controlled trials (RCTs) from PubMed, Cochrane Library database, and Clinicaltrials.gov (March 2012–March 2021), with no language, follow-up, or study size restrictions.
Inclusion criteria (based on the PICOS schema): (P) Patients with hypercholesterolemia or CVD; (I) PCSK9 inhibitors (assessing efficacy and safety of alirocumab, evolocumab, or bococizumab); (C) control (assessing efficacy and safety of control, i.e., placebo, usual care, or ezetimibe); (S) RCTs
Exclusion criteria: Abstracts, reviews, and case reports; no efficacy and safety data
Key Results
Of 1,820 studies, 45 RCTs (alirocumab vs evolocumab vs bococizumab: 21 vs 21 vs 3 RCTs) were included (N = 97,297 patients).
Lipid profile
In total, 42 RCTs (N = 92,681) reported data on TG, TC, LDL-C, and HDL-C
PCSK9 inhibitors could significantly reduce LDL-C, TC, and TG and increase HDL-C vs the control.
Alirocumab vs control:
Reduced LDL-C by –51.29% (95% confidence interval [CI]: –55.83 to –46.75, P <0.05), TC by –30.31% (95% CI: –34.26 to –26.36, P <0.05), and TG by –10.31% (95% CI: –13.81 to –6.81, P <0.05)
Increased HDL-C by 5.63% (95% CI: 4.86–6.40, P <0.05))
Evolocumab vs control:
Reduced LDL-C by –53.99% (95% CI: –58.45 to –49.54, P <0.05), TC by –34.2% (95% CI: –36.18 to –32.21, P <0.05), and TG by –8.86% (95% CI: –13.17 to –4.55, P <0.05)
Increased HDL-C by 7.05% (95% CI: 5.55–8.54, P <0.05)
Bococizumab vs control:
Reduced LDL-C by –56.96% (95% CI: –60.69 to –53.23, P <0.05), TC by –38.96% (95% CI: –43.33 to –34.58, P <0.05), and TG by –17.64% (95% CI: –20.79 to –14.48, P <0.05)
Increased HDL-C by 5.98% (95% CI: 4.86–7.11, P <0.05)
Cardiac disorders
Unstable angina (UA) was reported in 13 studies (N = 57,717) and myocardial infarction (MI) in 16 studies (N = 90,355).
UA was less common in the alirocumab group vs control (odds ratio [OR] = 0.69, 95% CI: 0.48–0.98, P <0.05) as was the frequency of MI (OR = 0.85, 95% CI: 0.76–0.95, P <0.05).
The risk of UA did not differ significantly between evolocumab and control group (OR = 0.66, 95% CI: 0.42–1.03, P >0.05); however, the risk of MI was lower with evolocumab (OR = 0.73, 95% CI: 0.65–0.82, P <0.05).
No statistically significant difference in UA (OR = 0.82, 95% CI: 0.67–1.00, P = 0.05) and MI (OR = 0.94, 95% CI: 0.78–1.14, P >0.05) was found between bococizumab and control groups./span>
Stroke
Incidence of stroke was significantly lower with PCSK9 inhibitors compared with control: Alirocumab (OR = 0.76, 95% CI: 0.60–0.97, P <0.05), evolocumab (OR = 0.79, 95% CI: 0.66–0.95, P <0.05), and bococizumab (OR = 0.60, 95% CI: 0.42–0.84, P <0.05)
Safety
Incidence of injection-site reactions was significantly higher with PCSK9 inhibitors vs control: Alirocumab (OR = 1.68, 95% CI: 1.45–1.93, P <0.05), evolocumab (OR = 1.64, 95% CI: 1.41–1.91, P <0.05), and bococizumab (OR = 8.03, 95% CI: 6.85–9.41, P <0.05)
Incidence of myalgia did not differ significantly between the control and alirocumab (OR = 1.18, 95% CI: 0.92–1.53), evolocumab (OR = 1.09, 95% CI: 0.85–1.38), and bococizumab (OR = 1.05, 95% CI: 0.92–1.20) (all, P >0.05).
Limitations
PCSK9 inhibitor dose and different follow-up durations may have affected heterogeneity of results.
Pooling of data in control group was a mixture of placebo or ezetimibe.
Definitions of efficacy and safety were not uniform in the included studies.
Geng Q, Li X, Sun Q, Wang Z. Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials. Cardiol J. 2021. doi: 10.5603/CJ.a2021.0110. Epub ahead of print. PMID: 34581425.
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website. Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.